4/A//SEC Filing
BIOS Fund II NT, LP 4/A
Accession 0001104659-24-091370
CIK 0001652935other
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 8:45 PM ET
Size
29.4 KB
Accession
0001104659-24-091370
Insider Transaction Report
Form 4/AAmended
BIOS Fund I QP, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP) - Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP)
Bios Equity Partners, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
BIOS Fund II NT, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
Kreis Leslie W.
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
Cavu Management, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP)
Cavu Advisors, LLC
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
BIOS Fund I, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
BIOS Fund II, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
BIOS Fund II QP, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
Bios Equity Partners II, LP
Director10% Owner
Transactions
- Sale
Common Stock
2024-08-14$8.00/sh−5,314$42,512→ 300,143 total(indirect: Directly held by Bios Fund II, LP) - Sale
Common Stock
2024-08-14$8.00/sh−17,361$138,888→ 980,433 total(indirect: Directly held by Bios Fund II QP, LP) - Sale
Common Stock
2024-08-14$8.00/sh−2,324$18,592→ 131,248 total(indirect: Directly held by Bios Fund II NT, LP)
Footnotes (7)
- [F1]On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares.
- [F2]The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct.
- [F3]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest").
- [F4]Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
- [F5]The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
- [F6]On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares.
- [F7]On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares.
Documents
Issuer
ACTUATE THERAPEUTICS, INC.
CIK 0001652935
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001728851
Filing Metadata
- Form type
- 4/A
- Filed
- Aug 19, 8:00 PM ET
- Accepted
- Aug 20, 8:45 PM ET
- Size
- 29.4 KB